Sign In
Buy RXST
$4.79
-0.150 (-3.04%)
At Close: Jun 03, 2026
RxSight downgraded to Hold from Buy at Stifel
07:55pm, Thursday, 19'th Dec 2024
Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads to believe that the risk from U.S. premium IOL - intra
Needham ups Alcon target, adds to Conviction List
02:12pm, Tuesday, 17'th Dec 2024
Needham earlier today raised the firm's price target on Alcon (ALC) to $108 from $103 and kept a Buy rating on the shares. The firm also added the stock to its Conviction List, replacing RxSight (RXST
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
12:04pm, Friday, 29'th Nov 2024
RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, repr
RxSight (RXST) Upgraded to Buy: Here's What You Should Know
01:00pm, Wednesday, 20'th Nov 2024
RxSight (RXST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript
01:32pm, Saturday, 09'th Nov 2024
RxSight, Inc. (NASDAQ:RXST ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President, Chief Execu
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3
08:01pm, Thursday, 07'th Nov 2024
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.35 per share a year ago.
RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
04:05pm, Thursday, 24'th Oct 2024
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
04:05pm, Thursday, 22'nd Aug 2024
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients followi
Investing In The Future Of Cataract Surgery: The RxSight Advantage
04:50pm, Tuesday, 13'th Aug 2024
RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly e
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
10:55am, Monday, 12'th Aug 2024
The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
09:45pm, Monday, 05'th Aug 2024
RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
07:10pm, Monday, 05'th Aug 2024
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago.
RxSight, Inc. Reports Second Quarter 2024 Financial Results
04:05pm, Monday, 05'th Aug 2024
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients followin
The 3 Best Med Tech Stocks to Buy Now
11:20am, Monday, 05'th Aug 2024
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and heal
Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround
10:35am, Monday, 29'th Jul 2024
RxSight (RXST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
